Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 15;10:377. doi: 10.1038/s41598-019-57285-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Accumulation of SLUG is indispensable for the establishment of the memory phenotypes. (A) A crescendo expression pattern of SLUG and ZEB2 upon the chronic IL-1β exposure in A549 cells, followed by a decrescendo pattern after IL-1β withdrawal, determined by RT-qPCR. (B) Experimental design: in LS group, doxycycline was added to induce SLUG shRNA after 7 days of IL-1β treatment and removed together with IL-1β at day 21. (C) Relative SLUG expression by RT-qPCR in LS and HS cells compared to the untreated cells. (D–F) EMT markers, apoptosis resistance, and surface PD-L1 expression were evaluated in different EMT stages in LS and HS cells compared to the IL-1β-untreated cells. (G) Kaplan-Meier curves from the TCGA lung adenocarcinoma (LUAD) cohort showing the survival probability in patients with various levels of SLUG expression. (H) Expression of SMA and Fibronectin in the same cohort of patients (95% confidence interval). All results are reported as mean ± SEM unless indicated otherwise. ***P < 0.0002, ****P < 0.0001. See also Fig. S3.

HHS Vulnerability Disclosure